Moreover, BLBC is clinically aggressive and its pathogenesis is poorly understood, so it is a huge challenge, compared to other breast cancer subtypes such as hormone receptor-positive and HER2-positive tumors. This evidence concerns the gene ERBB2 and breast carcinoma.